RxDoctor Payments Data

Brian Carlson, DO

Family Medicine · Sarasota, FLNPI 1740420439

Payments from drug & device makers

$9,267in general payments, 2019–2025

Across 531 payments — averaging $17.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Amgen$771
  • AstraZeneca$606
  • Pfizer$556
  • Boehringer Ingelheim$528
  • Bayer$488
  • plus $5K from 47 others

What the payments were for

  • Food & beverage$9,14799%
  • Education$1201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,267 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$125,971
Medicare patients
257
Services billed
3,038

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban94$95,959
JardianceEmpagliflozin54$81,681
OzempicSemaglutide50$62,986
Trelegy ElliptaFluticasone/Umeclidin/Vilanter44$41,360
MounjaroTirzepatide18$40,348
JanuviaSitagliptin Phosphate25$39,548
FarxigaDapagliflozin Propanediol24$36,038
XareltoRivaroxaban35$26,927
RybelsusSemaglutide13$26,527
Tresiba Flextouch U-200Insulin Degludec21$26,055
MyrbetriqMirabegron25$16,855
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog11$15,453
Combivent RespimatIpratropium/Albuterol Sulfate17$9,928
Paliperidone ErPaliperidone21$6,838
SavellaMilnacipran Hcl13$6,640

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$556$95,95994 claims
Boehringer IngelheimJardiance, Combivent Respimat$528$91,60971 claims
Novo NordiskOzempic, Rybelsus$1,368$89,51363 claims
GSKTrelegy Ellipta$436$41,36044 claims
Lilly USA, LLCMounjaro$455$40,34818 claims
MerckJanuvia$99$39,54825 claims
AstraZenecaFarxiga$606$36,03824 claims
Johnson & JohnsonXarelto$166$26,92735 claims
Astellas Pharma US IncMyrbetriq, Vesicare$217$21,28637 claims
AbbVieSavella, Synthroid$330$8,37330 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Sarasota

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →